Vontobel Holding Ltd. Has $1.13 Million Holdings In Exact Sciences Co. (NASDAQ:EXAS)

Vontobel Holding Ltd. Has .13 Million Holdings In Exact Sciences Co. (NASDAQ:EXAS)

Vontobel Holding Ltd. sold its interest to Exact Sciences Co. (NASDAQ: EXAS – Get Rating ) by 25.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,851 shares of the medical research company’s stock after acquiring an additional 5,621 shares during the period. Vontobel Holding AG's holdings in Exact Sciences were worth $1,130,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Capital Advisory Group Advisory Services LLC acquired a new position in shares of Exact Sciences in the first quarter worth about $37,000. Trustcore Financial Services LLC acquired a new stake in Exact Sciences in the first quarter valued at about $41,000. Koshinski Asset Management Inc. grew its position in Exact Sciences by 45.5% in the first quarter. Koshinski Asset Management Inc. now owns 640 shares of the medical research company’s stock valued at $45,000 after buying an additional 200 shares in the last quarter. Elequin Capital LP acquired a new stake in Exact Sciences during the first quarter worth about $46,000. Finally, in the second quarter, Ellevest Inc. It increased its positions in the field of exact sciences by 103.6%. Now Ellevest Inc. now owns 682 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 347 shares in the last quarter. 90.95% of shares are owned by institutional investors and hedge funds.

Preferential buying and selling

In related news, director Catherine S. Zanotti sold 4,608 shares of the business’s stock in a transaction on Tuesday, July 26th. Shares traded at an average price of $45.14, for a total of $208,005.12. Following the sale, the director now owns 60,318 shares in the company, valued at approximately $2,722,754.52. The sale was announced in a filing with the Securities and Exchange Commission, available at this link. In related news, director Catherine S. Zanotti sold 4,608 shares of the business’s stock in a transaction on Tuesday, July 26th. Shares traded at an average price of $45.14, for a total of $208,005.12. Following the sale, the director now owns 60,318 shares in the company, valued at approximately $2,722,754.52. The sale was announced in a filing with the Securities and Exchange Commission, available at this link. Also, insider Everett Cunningham sold 16,872 shares of Exact Sciences stock in a transaction dated Wednesday, October 12th. Shares were sold at an average price of $31.37, for a total of $529,274.64. Following the completion of the sale, the insider now directly owns 18,654 shares of the company's stock, valued at approximately $585,175.98. Information on this sale can be found here. Currently, 1.30% of shares are owned by insiders.

See also  Life Sciences VC Firm Expands To Boston, Signs 58K SF Lease With Beacon Capital

Analysts have set new pricing benchmarks

A number of equities research analysts recently commented on the company. BTIG Research reduced their price objective on Exact Sciences to $70.00 from $100.00 and gave the stock a “buy” rating in a report on Wednesday, August 3rd. Credit Suisse Group assumed coverage on Exact Sciences in a research report on Wednesday, August 24th. They assigned an “outperform” rating and a $55.00 target price on the stock. Benchmark decreased their target price on Exact Sciences to $54.00 in a research report on Tuesday, August 9th. Raymond James decreased their target price on Exact Sciences to $70.00 from $80.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 3rd. Finally, Robert W. Baird decreased their price objective on Exact Sciences to $75.00 from $90.00 and gave the stock an outperform rating in a research report on Wednesday, August 3rd. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Moderate Buy” and a consensus target price of $69.14, according to MarketBeat .

Shares of Exact Sciences fell 3.8%

NASDAQ:EXAS opened at $30.42 on Friday. Exact Sciences Co. has a 12-month low of $29.27 and a 12-month high of $104.50. The company has a quick ratio of 2.23, a current ratio of 2.48, and a debt-to-equity ratio of 0.70. The company has a market cap of $5.38 billion, a p/e of -7.19 and a beta of 1.34. The 50 day simple moving average is $37.41 and the 200 day simple moving average is $47.05.

See also  Report Highlights Growth Of Life Sciences Sector In Seattle, Buoyed By NIH Funding

Exact Sciences (NASDAQ: EXAS – Get Rating ) last posted its quarterly earnings results on Tuesday, August 2nd. The medical research company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.13. Exact Sciences had a negative return on equity of 22.07% and a negative net margin of 37.90%. The company reported revenue of $521.64 million for the quarter, compared to analyst estimates of $496.75 million. Stock analysts expect Exact Sciences Co. Earnings per share for the reporting year is -4.22.

Accurate academic profile

(evaluate)

Exact Sciences Corporation provides cancer screening products and diagnostic tests in the United States and internationally. The company offers Cologuard, a noninvasive stool-based DNA screening test for the detection of DNA and hemoglobin biomarkers associated with colorectal cancer and precancerous lesions. It also offers Oncotype DX, a gene expression test for breast, prostate and colon cancers; Oncotype testing, a tissue analysis that creates a tumor profile to help guide therapy choices for patients with advanced, metastatic, refractory, or relapsed cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid test for advanced prostate cancer; Oncomap ExTra, which provides a complete biological picture of certain refractory, rare or aggressive tumors; and COVID-19 testing services.

Further reading

Want to see what other hedge funds EXAS has? Visit HoldingsChannel.com for Exact Sciences Co's latest 13F filings and insider trading. (NASDAQ: EXAS – Get Ratings ).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ: EXAS )

Get Daily Exact Sciences News & Ratings – Enter your email below. to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com 's FREE daily newsletter.

See also  Revolutionizing the World Through Sciences

Leave a Comment